Loading clinical trials...

Tear Lipid Layer Thickness With Emollient Eye Drops | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624•Ohio State University

View on ClinicalTrials.gov

Summary

Crossover comparison of lipid layer thickness with two artificial tear formulations

Detailed Description

This study will objectively evaluate two US Monograph lubricant eyedrop formulations (Allergan, plc). Refresh Optive ADVANCED will be compared to an investigational formula with additional compendial ingredients (Refresh Optive MEGA 3) in subjects with dry eye symptoms and lipid layer thickness \< 75 nm at baseline in a randomized, cross-over (masked subject) design. We seek to objectively evaluate the increase in lipid layer thickness from baseline at 15 minutes and 1 hour after each eye drop has been instilled. The Stroboscopic Video Color Microscope of King-Smith is used for non-invasive lipid layer thickness measurement.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age - at least 30 years
•* Good general health (defined by medication use that has not changed within the last month and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the PI)
•* Ability to give informed consent
•* Willing to spend time for the study; approximately one hour for a screening visit and additional 4 hours for the study assessments. Study assessment will be conducted over 2 visit days, approximately 1 1/2 hours per day.
•* Either gender
•* Any racial or ethnic origin
•* Stroboscopic Video Color Microscope tear lipid thickness ≤ 75 nm

Exclusion Criteria

•Use of any ocular prescription medication (such as but not limited to, glaucoma medications, anti-inflammatory eye drops and Restasis) used within 14 days of the screening visit or started prior to the measurement visit(s).
•* Currently having punctal plugs inserted in lacrimal puncta
•* Current eye disease, infection or inflammation that affects the surface of the eye such as, but not limited to moderate or greater blepharitis and ocular allergy. Clinically significant (active treatment) of blepharitis, Sjogren's disease or other systemic disease that could influence Meibomian Gland Dysfunction, corneal, conjunctival, or eyelid abnormalities that could influence lipid layer thickness, conjunctivitis of any cause, ocular infection or systemic medication such as diuretics or drugs that could influence tear secretion, or sensitivity to any of the ingredient in the eye drop being tested,
•* Past eye surgery, such as, but not limited to, refractive surgery. Subjects who have had cataract removal surgery more than one year ago, but less than 10 years ago may be considered as potential subjects.
•* Female subjects may not be pregnant or lactating. (Subject will be asked to self report these conditions.)
•* Infectious diseases (for example, hepatitis, tuberculosis) or an immuno-suppressive disease (for example, HIV). (Subjects will be asked to self-report these conditions.)
•* Inability to complete the screening and examination
•* Inability to provide analyzable data. For example, subjects who cannot keep their eye open during the entire measurement interval (due to early blinking) or provide a readable eye image (due to eyelid laxity) or cannot sit still for 1 minute.

Locations (1)

The Ohio State University

Columbus, Ohio, United States

Key Dates

Start Date

March 1, 2017

Primary Completion Date

June 30, 2018

Completion Date

June 30, 2018

Last Updated

February 3, 2021

Enrollment

ACTUAL participants

Conditions

Dry Eye Syndromes

Interventions

Refresh Optive

DRUG

Refresh Optive MEGA-3

DRUG

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327

Multiple SclerosisDry Eye Syndromes+4 more

View study

RECRUITINGNA

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

NCT06220474

Dry Eye SyndromesMeibomian Gland Dysfunction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Tear Lipid Layer Thickness With Emollient Eye Drops

Inclusion Criteria

Exclusion Criteria

Clinical Applications of Advanced Ophthalmic Imaging

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction